Showing results (961-970 of 1,324) with videos related to
Sort By:
Pageof 133
CNS & Neurological Disorders Drug Targets|December 4, 2014
Cognitive dysfunction in depression - pathophysiology and novel targetsAndre F Carvalho, Kamilla K Miskowiak, Thomas N Hyphantis, et al.Innovations in Clinical Neuroscience|April 6, 2022
Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC)Leslie Citrome, Anissa Abi-Dargham, Robert M Bilder, et al.Journal of Psychopharmacology (Oxford, England)|July 1, 2025
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depressionRyan M Brudner, Erica Kaczmarek, Marc G Blainey, et al.European Journal of Psychotraumatology|February 21, 2022
Meta-analytic evidence of depression and anxiety in Eastern Europe during the COVID-19 pandemicStephen X Zhang, Saylor O Miller, Wen Xu, et al.The Primary Care Companion for CNS Disorders|November 12, 2016
Functional Recovery in Major Depressive Disorder: Focus on Early Optimized TreatmentJeffrey Habert, Martin A Katzman, Oloruntoba J Oluboka, et al.Bjpsych Open|February 16, 2021
Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controlsNanna Aagaard Petersen, Marc Østergaard Nielsen, Klara Coello, et al.Blood|June 5, 2013
Notch-HES1 signaling axis controls hemato-endothelial fate decisions of human embryonic and induced pluripotent stem cellsJung Bok Lee, Tamra E Werbowetski-Ogilvie, Jong-Hee Lee, et al.The Journal of Clinical Psychiatry|January 30, 2020
A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive DyskinesiaStanley N Caroff, Leslie Citrome, Jonathan Meyer, et al.Journal of Psychiatric Research|March 9, 2020
Effect of body anthropometrics on brain structure of offspring of parents with bipolar disorderMehala Subramaniapillai, Rodrigo B Mansur, Yan Chen, et al.Med (New York, N.Y.)|November 11, 2025
Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trialSebastian Badulescu, Hartej Gill, Hiya Shah, et al.Pageof 133